For the DMAs result between the other individual diabetes medications and BP, the alpha-glucosidase inhibitors, meglitinides and sulfonylureas showed disproportionality regardless of whether excluding case subjects who received DPP-4 inhibitors, but the incretin mimetics (also known as GLP-1 Agonists), insulin, SGLT-2 inhibitors and thiazolidinediones did not show disproportionality regardless of whether excluding case subjects who received DPP-4 inhibitors. This evidence concerns the gene GCG and diabetes mellitus.